dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 18, 2026

Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider

View original at globenewswire.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A majority of Turner syndrome patients are unaware of their condition until they enter adolescence

    80% confidence
  • The U.S. leads globally in orphan drug approvals for chromosomal conditions

    80% confidence
  • North America dominated the Turner syndrome market in 2025 with a 37.70% revenue share

    80% confidence
  • The U.S. Turner Syndrome Market size was valued at an estimated USD 0.52 Billion in 2025 and is projected to reach USD 0.96 Billion by 2033, growing at a CAGR of 8.12% over the forecast period 2026–2033

    80% confidence
  • The Asia-Pacific region is expected to grow at the highest CAGR of 9.43%

    80% confidence
  • Turner syndrome occurs in 1 out of every 2,500 female newborns

    80% confidence
  • The Turner Syndrome Market was valued at USD 1.93 Billion in 2025 and is projected to reach USD 3.67 Billion by 2033, reflecting a compound annual growth rate (CAGR) of 8.39% from 2026 to 2033

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider: Source | Via News | fr.via.news